QURE uniQure N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590560 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.0%
TTM net income YoY1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR-43.5%
Net income 3-yr CAGR—
Margins
Gross margin93.9%
Operating margin-1,001.7%
Net margin-1,154.8%
FCF margin-956.8%
EBITDA margin-921.0%
Returns
ROE-89.0%
ROA-25.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets68.7%
Debt / equity0.17x
Current ratio11.52x
Interest coverage-3.51x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.20M | $5.84M | $3.56M | $5.57M | $3.70M | $5.26M | $1.57M | $5.22M |
| Cost of revenue | $236,000 | $350,000 | $219,000 | $435,000 | $398,000 | $656,000 | $197,000 | $619,000 |
| Gross profit | $4.96M | $5.49M | $3.34M | $5.13M | $3.30M | $4.61M | $1.37M | $4.60M |
| R&D expense | $35.52M | $33.96M | $29.18M | $34.78M | $34.37M | $35.38M | $36.14M | $38.84M |
| SG&A expense | $23.92M | $17.37M | $20.07M | $21.61M | $19.44M | $13.50M | $10.91M | $11.38M |
| Operating income | -$52.98M | -$52.20M | -$45.72M | -$51.12M | -$51.03M | -$43.87M | -$39.33M | -$45.83M |
| Interest expense | $14.58M | $14.37M | $14.03M | $14.57M | $16.72M | $15.59M | $15.11M | $14.88M |
| Pretax income | -$60.54M | -$79.22M | -$53.05M | -$41.00M | -$71.90M | -$37.29M | -$43.14M | -$72.41M |
| Income tax | $676,000 | $1.84M | $488,000 | -$3.92M | $8.63M | $425,000 | $496,000 | $856,000 |
| Net income | -$61.22M | -$81.06M | -$53.53M | -$37.09M | -$80.53M | -$37.72M | -$43.64M | -$73.26M |
| EBITDA | -$47.53M | -$47.30M | -$42.76M | -$48.15M | -$47.40M | -$40.23M | -$34.80M | -$44.01M |
| EPS (basic) | -0.88 | -1.22 | -0.85 | — | -1.38 | -0.69 | -0.82 | — |
| EPS (diluted) | -0.88 | -1.22 | -0.85 | — | -1.38 | -0.69 | -0.82 | — |
| Weighted avg. shares (diluted) | 69.90M | 66.24M | 62.74M | — | 58.52M | 54.81M | 53.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $98.44M | $413.03M | $139.99M | $80.24M | $597.06M | $253.78M | $217.23M | $160.33M |
| Receivables | $4.80M | $5.78M | $3.56M | $5.86M | — | — | — | — |
| Current assets | $692.54M | $834.27M | $615.74M | $655.99M | $716.19M | $408.57M | $435.42M | $390.29M |
| PP&E, net | $9.92M | $11.38M | $12.01M | $13.80M | $15.40M | $17.49M | $18.08M | $20.42M |
| Goodwill | $24.50M | $24.59M | $24.81M | $25.36M | $25.33M | $25.34M | $23.35M | $22.41M |
| Intangibles | $61.85M | $62.10M | $69.99M | $72.79M | $74.14M | $75.60M | $71.99M | $71.04M |
| Total assets | $940.55M | $985.10M | $778.71M | $824.91M | $888.38M | $584.89M | $605.40M | $556.54M |
| Current liabilities | $60.14M | $83.34M | $59.20M | $62.92M | $100.63M | $40.93M | $36.31M | $40.05M |
| Long-term debt | $50.34M | $50.15M | $49.94M | $49.70M | $51.88M | $51.84M | $51.59M | $51.32M |
| Total debt | $50.34M | $50.15M | $49.94M | $49.70M | $51.88M | $51.84M | $51.59M | $51.32M |
| Total liabilities | $645.90M | $661.05M | $629.36M | $626.01M | $659.64M | $588.89M | $571.72M | $563.29M |
| Shareholders' equity | $294.65M | $324.05M | $149.34M | $198.90M | $228.75M | -$4.00M | $33.69M | -$6.75M |
| Net debt | -$48.10M | -$362.88M | -$90.05M | -$30.54M | -$545.18M | -$201.94M | -$165.64M | -$109.00M |
| Shares outstanding | 70.04M | 69.33M | 63.03M | 62.34M | 62.17M | 54.87M | 54.70M | 48.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47.83M | -$28.58M | -$38.24M | -$77.57M | -$16.40M | -$39.90M | -$44.10M | -$52.84M |
| Capital expenditure | $11,000 | $472,000 | $140,000 | $119,000 | -$66,000 | $260,000 | $126,000 | $40,000 |
| Free cash flow | -$47.84M | -$29.05M | -$38.38M | -$77.69M | -$16.33M | -$40.16M | -$44.23M | -$52.88M |
| Investing cash flow | -$268.73M | $53.26M | $98.56M | -$441.37M | $26.58M | $73.07M | $20.10M | -$26.62M |
| Financing cash flow | $1.56M | $249.12M | $550,000 | $2.45M | $332.24M | $44,000 | $80.67M | -$6.52M |
| Depreciation & amortization | $5.45M | $4.91M | $2.96M | $2.97M | $3.63M | $3.63M | $4.53M | $1.81M |
| Stock-based compensation | $5.45M | $5.02M | $5.09M | $4.66M | $3.52M | $5.08M | $4.41M | $4.75M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.